Introducing Xandr Monetize
5.9.2019 16:00:00 EEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising & analytics company, today announced the launch of Xandr Monetize, a reimagined strategic selling platform built on the powerful foundation of AppNexus technology. Xandr Monetize will enable media companies to unlock the full value of their premium content and improve the advertising experience for consumers.
As content consumption and viewer attention increasingly fragment, Xandr Monetize gives publishers and media owners full control to navigate the consumer journey and client relationships. The platform offers content owners improved monetization, through better inventory management capabilities, data-driven yield optimization, and differentiated buyer demand. With these powerful tools, Xandr Monetize expands the ways in which publishers can package, sell, and measure the performance of their inventory across all screens and devices.
“Xandr is a trusted partner to media companies, attuned to their challenges and innovating in support of their growth. Now, with the size, scale, and resources of AT&T, we are uniquely positioned to offer the scaled, streamlined selling platform the industry needs,” said Ryan Christensen, SVP of Product, Xandr. “With the launch of Xandr Monetize, our future is primed for collaboration that expands and enriches what media companies offer their advertisers and consumers.”
Monetize Together
Xandr Monetize encompasses all the features of the former AppNexus seller products, including an ad server, supply-side platform (SSP), and yield analytics, and now lays the infrastructure for powerful TV capabilities. The platform unifies and simplifies operations across all inventory and transaction types, as well as demand channels. This allows publishers and media owners to focus on creating more content, innovating with advertising formats, and attracting interested consumers.
“The reality for premium publishers in today’s market is that the major platforms are self-interested, yet Xandr’s goals have been consistently aligned with publishers on the open internet. By collaborating closely with us to differentiate our business and innovating to offer buying the way that advertisers want it, Xandr has enabled us to thrive outside of closed ecosystems. Through premium deals and holistic demand channel management, Xandr Monetize sets us up to strategically optimize global revenue,” said Carsten Schwecke, Chairman of the Board, Media Impact, the joint marketing organization of Axel Springer and Funke Mediengruppe.
Xandr Monetize rounds out Xandr’s platform offering of strategic buying and selling solutions. The direct path between Xandr Invest, the strategic buying platform, and Xandr Monetize facilitates scaled buying and unique demand from AT&T, maximizing working media dollars for buyers and direct sellers alike. Xandr Monetize also allows media companies to sell their inventory through Community, Xandr’s curated premium advertising marketplace, to achieve better yield on their premium multiplatform inventory. Buying access to Community is available solely through Xandr Invest.
Monetize for the Future
While building for the future of monetization, Xandr is already tackling the challenges that digital video buyers and sellers face today. The introduction of Programmatic OTT with Prebid brings programmatic demand to TV by enabling competitive separation across multiple SSPs, on Connected TV devices and other digital TV inventory. Xandr’s Programmatic OTT with Prebid offers greater control on par with TV norms, including brand safety and frequency capping, while supporting simultaneous competition for inventory by all programmatic demand. It is available through real-time bidding and deals.
“Developed with our sales needs in mind, Programmatic OTT with Prebid will be essential to better managing inventory within client campaigns and realizing higher yield for our premium content. We have already tested it and are very excited to deploy this capability across the WarnerMedia digital portfolio,” said Amit Chaturvedi, EVP, Head of Revenue Operations & Ad Products, WarnerMedia Ad Sales.
The launch of Xandr Monetize also introduces Prebid Server Premium, Xandr’s simplified server-side header bidding solution, for both SSP and ad server customers. As server-side header bidding opens new channels of header bidding demand and improves site performance, Prebid Server Premium simplifies setup and increases operational efficiency through reporting insights across formats and a single source of clearing across SSPs.
Xandr Monetize offers holistic inventory and demand channel management so media companies can capitalize on the convergence of direct-sold and programmatic campaigns and maximize the value of their inventory. In addition to robust deal capabilities, Xandr now offers Programmatic Guaranteed, allowing publishers to pre-agree with, and execute on, reserved delivery commitments with programmatic buyers without compromising control over how their inventory is monetized.
Foundational to Xandr Monetize are industry-leading forecasting analytics and data-driven yield optimization. Yield analytics, formerly Yieldex, brings a long history of forecasting insights development with unparalleled accuracy. This allows for planning, pacing, and decisioning for direct and programmatic selling throughout the Xandr Monetize product suite, including current and future TV solutions and the ad server.
“Microsoft relies on Xandr as a programmatic advertising partner that can operate at the massive global scale MSN, Outlook, Xbox, and our Windows App Developers require. Over the last ten years of working together, Xandr has been a thoughtful and flexible partner that has helped Microsoft be successful in our rapidly-changing marketplace and with our unique platform needs. The innovation we’ve seen in Xandr Monetize has augmented our programmatic revenue, while simplifying our ad stack. We look forward to continuing our strategic collaboration and pushing the envelope with the future of advertising,” said Kya Sainsbury-Carter, GM of Global Partner Services, Microsoft.
About Xandr
Xandr is AT&T’s advertising company and a leader in addressable TV, creating a better solution for advertisers and media companies. Xandr Invest and Xandr Monetize, our strategic platforms built on more than a decade of AppNexus’ innovation, optimize media spend across screens for buyers and sellers alike. Community, powered by Xandr, is a curated marketplace of premium publishers, providing access to unique consumer insights in a brand-safe environment. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005274/en/
Contact information
Xandr Press Contact
Caroline Smith
914.446.3006
caroline.smith@xandr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
